
Arthroplasty
Short- and long-course levofloxacin plus rifampicin for prosthetic joint infection
Int J Antimicrob Agents. 2016 Sep;48(3):310-663 patients with a hip or knee prosthetic joint infection by either Staphylococcus aureus or coagulase-negative staphylococci were randomized to either 8 weeks of levofloxacin and rifampicin following debridement, or 3- and 6-months levofloxacin and rifampicin following debridement (3 months for hip infection and 6 months for knee infection). The purpose of this study was to compare infection cure rates between groups. Results demonstrated no significant differences between groups in infection cure rate in either the intention-to-treat or per-protocol analyses. Study enrollment was terminated early due to slow enrollment, as a smaller number of patients presented with acute staphylococcal infection than expected, leading to a final cohort well below the calculated sample size required (195 patients).
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.